A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

被引：0

作者：

Quach, Hang ^{[1
]}

Parmar, Gurdeep ^{[2
]}

Ocio, Enrique M. ^{[3
]}

Prince, H. Miles ^{[4
,5
]}

Oriol, Albert ^{[6
,7
]}

Crowther, Helen ^{[8
]}

Tsukada, Nobuhiro ^{[9
]}

Bories, Pierre ^{[10
]}

Madan, Sumit ^{[11
]}

Nathwani, Nitya ^{[12
]}

Sunami, Kazutaka ^{[13
]}

Semiond, Dorothee ^{[14
]}

Yu, Disa ^{[14
]}

Cordero, Paul ^{[15
]}

Mace, Sandrine ^{[16
]}

Suzan, Florence ^{[16
]}

Moreau, Philippe ^{[17
]}

机构：

[1] Univ Melbourne, St Vincents Hosp, Clin Hematol Serv, Melbourne, Australia

[2] Illawarra Canc Care Ctr, Wollongong, Australia

[3] Univ Cantabria, Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[4] Epworth HealthCare, Mol Oncol & Canc Immunol, Melbourne, Australia

[5] Univ Melbourne, Melbourne, Australia

[6] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

[7] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

[8] Blacktown & Mt Druitt Hosp, Dept Paediat, Blacktown, NSW, Australia

[9] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[10] Inst Univ Canc Toulouse, Inst Claudius Regaud, Inst Claudius Regaud, Toulouse, France

[11] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[12] City Hope Natl Med Ctr, Dept Hematol, Duarte, CA USA

[13] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan

[14] Sanofi, Res & Dev, Cambridge, MA USA

[15] Sanofi, Res & Dev, Reading, England

[16] Sanofi, Res & Dev, Vitry Sur Seine, France

[17] Univ Hosp Nantes, Dept Hematol, Nantes, France

来源：

HAEMATOLOGICA | 2024年 / 109卷 / 12期

关键词：

OPEN-LABEL;

D O I：

10.3324/haematol.2023.284730

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4078 / 4082

页数：5

共 50 条

[41] Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression-A single center retrospective study
Regidor, Bernard Sean
Jew, Scott
Goldwater, Marissa-Skye
Beatty, Bethany Marie
Bujarski, Sean
ElSayed, Adam
Danis, Ryan
Kim, Susanna
Swift, Regina
Schwartz, Gary
Berenson, James R.
EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (04) : 628 - 635
[42] Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Mccurdy, Arleigh
Reece, Donna
Louzada, Martha L.
White, Darrell
Parkin, Stephen
Chu, Michael P.
Kotb, Rami
Mian, Hira
Othman, Ibraheem
Su, Jiandong
Khan, Aniba
Gul, Engin
Trudel, Suzanne
BLOOD CANCER JOURNAL, 2024, 14 (01):
[43] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
Capra, Marcelo
Martin, Thomas
Moreau, Philippe
Baker, Ross
Pour, Ludek
Min, Chang-Ki
Leleu, Xavier
Mohty, Mohamad
Reinoso Segura, Marta
Turgut, Mehmet
LeBlanc, Richard
Risse, Marie-Laure
Malinge, Laure
Schwab, Sandrine
Dimopoulos, Meletios
HAEMATOLOGICA, 2022, 107 (06) : 1397 - 1409
[44] Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation
Martin, Thomas G.
Capra, Marcelo
Mohty, Mohamad
Suzuki, Kenshi
Quach, Hang
Cavo, Michele
Moreau, Philippe
Dimopoulos, Meletios
Yong, Kwee
Tekle, Christina
Foster, Meredith C.
Barnes, Yvonne
Risse, Marie-Laure
Mikhael, Joseph
TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (02): : 134.e1 - 134.e7
[45] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
Dhakal, Binod
D'Souza, Anita
Hamadani, Mehdi
Arce-Lara, Carlos
Schroeder, Katrina
Chhabra, Saurabh
Shah, Nirav N.
Gauger, Katelyn
Keaton, Taylor
Pasquini, Marcelo
Hari, Parameswaran
BLOOD CANCER JOURNAL, 2019, 9 (8)
[46] Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Kumar, Shaji K.
LaPlant, Betsy R.
Reeder, Craig B.
Roy, Vivek
Halvorson, Alese E.
Buadi, Francis
Gertz, Morie A.
Bergsagel, P. Leif
Dispenzieri, Angela
Thompson, Melanie A.
Crawley, Jamie
Kapoor, Prashant
Mikhael, Joseph
Stewart, Keith
Hayman, Suzanne R.
Hwa, Yi L.
Gonsalves, Wilson
Witzig, Thomas E.
Ailawadhi, Sikander
Dingli, David
Go, Ronald S.
Lin, Yi
Rivera, Candido E.
Rajkumar, S. Vincent
Lacy, Martha Q.
BLOOD, 2016, 128 (20) : 2415 - 2422
[47] Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Papadopoulos, Kyriakos P.
Siegel, David S.
Vesole, David H.
Lee, Peter
Rosen, Steven T.
Zojwalla, Naseem
Holahan, Joseph R.
Lee, Susan
Wang, Zhengping
Badros, Ashraf
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07) : 732 - 739
[48] Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
Ocio, Enrique M. M.
Bringhen, Sara
Martinez-Lopez, Joaquin
San-Miguel, Jesus
Oliva, Stefania
Rodriguez-Otero, Paula
Le Roux, Nadia
Dong, Yvonne
Doroumian, Severine
Mace, Sandrine
Mateos, Maria-Victoria
HEMASPHERE, 2023, 7 (02):
[49] Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
Gentile, Massimo
Vigna, Ernesto
Palmieri, Salvatore
Galli, Monica
Derudas, Daniele
Mina, Roberto
Della Pepa, Roberta
Zambello, Renato
Martino, Enrica Antonia
Bruzzese, Antonella
Mangiacavalli, Silvia
Zamagni, Elena
Califano, Catello
Musso, Maurizio
Conticello, Concetta
Cerchione, Claudio
Mele, Giuseppe
Di Renzo, Nicola
Offidani, Massimo
Tarantini, Giuseppe
Casaluci, Gloria Margiotta
Rago, Angela
Ria, Roberto
Uccello, Giuseppina
Barila, Gregorio
Palumbo, Gaetano
Pompa, Alessandra
Vincelli, Donatella
Brunori, Marino
Accardi, Fabrizio
Amico, Valeria
Amendola, Angela
Fontana, Raffaele
Bongarzoni, Velia
Rossini, Bernardo
Cotzia, Emilia
Gozzetti, Alessandro
Rizzi, Rita
Sgherza, Nicola
Ferretti, Eleonora
Bertuglia, Giuseppe
Nappi, Davide
Petrucci, Maria Teresa
Di Raimondo, Francesco
Neri, Antonino
Morabito, Fortunato
Musto, Pellegrino
HAEMATOLOGICA, 2024, 109 (01) : 245 - 255
[50] Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study
Lee, Ji Hyun
Choi, Jimin
Min, Chang-Ki
Park, Sung-Soo
Jo, Jae-Cheol
Lee, Yoo Jin
Kim, Jin Seok
Eom, Hyeon-Seok
Jung, Jongheon
Moon, Joon Ho
Cho, Hee Jeong
Lee, Myung-won
Yoon, Sung-Soo
Byun, Ja Min
Lee, Jae Hoon
Lee, Je-Jung
Jung, Sung-Hoon
Shin, Ho-Jin
Kim, Do Young
Yi, Jun Ho
Lee, Seung-Shin
Do, Young Rok
Yoon, Dok Hyun
Cho, Hyungwoo
Lee, Won Sik
Lee, Ho Sup
Uhm, Jieun
Kim, Hyo Jung
Jang, Hee Ryeong
Kim, Sung-Hyun
Kim, Kihyun
HAEMATOLOGICA, 2024, 109 (11) : 3681 - 3692

← 1 2 3 4 5 →